[Treatment of bronchial hypersecretion. Demonstration of polyanionic mucins-eprazinone interactions].
The study of therapeutical agents for "mucolysis" enables a classification of these drugs from their mode of action at the trachea-bronchial level (pharmacodynamic agents, enzymes, reducers, mucoregulation). The affinity of a piperazine derivative, eprazinone, for polyanionic bronchial mucins, was shown in vitro by spectrophotometry. Because of this property, eprazinone (Mucitux) might modify the fibrillar structure of bronchial mucus. This mode of action would differentiate this treatment from the mucolytic agents used today clinically.
D001980:Bronchi / Q000378:metabolism; D001991:Bronchitis / Q000188:drug therapy; D004347:Drug Interactions; D005100:Expectorants / Q000627:therapeutic use*; D006801:Humans; D009077:Mucins; D009093:Mucus / Q000187:drug effects; D010879:Piperazines / Q000627:therapeutic use*; D011427:Propiophenones / Q000627:therapeutic use*; D012794:Sialic Acids; D013054:Spectrophotometry, Atomic; D013431:Sulfates; D014048:Tolonium Chloride
D005100:Expectorants; D009077:Mucins; D010879:Piperazines; D011427:Propiophenones; D012794:Sialic Acids; D013431:Sulfates; D014048:Tolonium Chloride; C007608:eprazinone
Traitement de l'hypersécrétion bronchique. Mise en évidence d'interactions mucines polyanioniques-éprazinone